Article Data

  • Views 872
  • Dowloads 166

Editorials

Open Access

Capillary leak syndrome in COVID-19 and post COVID-19 vaccines

  • Luca Roncati1,*,
  • Greta Gianotti1
  • Elisa Ambrogi1
  • Giovanna Attolini1

1Department of Surgery, Medicine, Dentistry and Morphological Sciences with interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 41124 Modena, Italy

DOI: 10.31083/j.ejgo4205126 Vol.42,Issue 5,October 2021 pp.829-831

Submitted: 16 August 2021 Accepted: 23 August 2021

Published: 15 October 2021

*Corresponding Author(s): Luca Roncati E-mail: uca.roncati@unimore.it; roncati.luca@aou.mo.it; emailmedical@gmail.com

Cite and Share

Luca Roncati,Greta Gianotti,Elisa Ambrogi,Giovanna Attolini. Capillary leak syndrome in COVID-19 and post COVID-19 vaccines. European Journal of Gynaecological Oncology. 2021. 42(5);829-831.

References

[1] Tsibulak I, Reiser E, Bogner G, Petru E, Hell-Teutsch J, Reinthaller A, et al. Decrease in gynecological cancer diagnoses during the COVID-19 pandemic: an Austrian perspective. International Journal of Gynecologic Cancer. 2020; 30: 1667–1671.

[2] Roncati L, Gianotti G, Ambrogi E, Attolini G. COVID-19 in pregnancy. Clinical and Experimental Obstetrics & Gynecology. 2021; 48: 778.

[3] Roncati L, Ligabue G, Nasillo V, Lusenti B, Gennari W, Fabbiani L, et al. A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients. Platelets. 2020; 31: 1085–1089.

[4] Gourd E. COVID-19 pandemic causes cervical cancer screening crisis. The Lancet Oncology. 2021; 22: 1060.

[5] Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020; 10: 783–791.

[6] Roncati L, Nasillo V, Lusenti B, Riva G. Signals of Th2 immune response from COVID-19 patients requiring intensive care. Annals of Hematology. 2020; 99: 1419–1420.

[7] Roncati L, Roncati M. Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic. Journal of Public Health Policy. 2021. (in press)

[8] McKean N, Chircop C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Reports. 2021; 14: e244125.

[9] Hasan T, Khan M, Khan F, Hamza G. Case of Guillain-Barré syndrome following COVID-19 vaccine. BMJ Case Reports. 2021; 14: e243629.

[10] Patel SU, Khurram R, Lakhani A, Quirk B. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirusvectored COVID-19 vaccine, ChAdOx1. BMJ Case Reports. 2021; 14: e242956.

[11] Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine. 2021; 384: 2202–2211.

[12] Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine. 2021; 384: 2124–2130.

[13] Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine. 2021; 384: 2092–2101.

[14] European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). 2021. Available at: https://www.ema.europa.eu/en/documents/product-infor mation/vaxzevria-previously-covid-19-vaccine-astrazeneca-epa

r- product-information_en.pdf (Accessed: 19 July 2021).

[15] European Medicines Agency. COVID-19 Vaccine Janssen. 2021. Available at: https://www.ema.europa.eu/en/documents/produ ct-information/covid-19-vaccine-janssen-epar-product-infor mation_en.pdf (Accessed: 4 August 2021).

[16] European Medicines Agency. Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. 2021. Available at: https://www.ema.europa.eu/en/news/vaxzevria-ema-a dvises-against-use-people-history-capillary-leak-syndrome (Accessed: 11 June 2021).

[17] European Medicines Agency. EMA advises against use of COVID-19 Vaccine Janssen in people with history of capillary leak syndrome. 2021. Available at: https: //www.ema.europa.eu/en/news/ema-advises-against-use-cov id-19-vaccine-janssen-people-history-capillary-leak-syndrome (Accessed: 9 July 2021).

[18] Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney International. 2017; 92: 37–46.

[19] Kapoor P, Greipp PT, Schaefer EW, Mandrekar SJ, Kamal AH, Gonzalez-Paz NC, et al. Idiopathic systemic capillary leak syndrome (Clarkson’s disease): the Mayo clinic experience. Mayo Clinic Proceedings. 2010; 85: 905–912.

[20] Pineton de Chambrun M, Luyt C, Beloncle F, Gousseff M, Mauhin W, Argaud L, et al. The Clinical Picture of Severe Systemic Capillary-Leak Syndrome Episodes Requiring ICU Admission. Critical Care Medicine. 2017; 45: 1216–1223.

[21] Clarkson B, Thompson D, Horwith M, Luckey EH. Cyclical edema and shock due to increased capillary permeability. The American Journal of Medicine. 1960; 29: 193–216.

[22] Pineton de Chambrun M, Cohen-Aubart F, Donker DW, Cariou P, Luyt C, Combes A, et al. SARS-CoV-2 Induces Acute and Refractory Relapse of Systemic Capillary Leak Syndrome (Clarkson’s Disease). The American Journal of Medicine. 2020; 133: e663–e664.

[23] Cheung PC, Eisch AR, Maleque N, Polly DM, Auld SC, Druey KM. Fatal exacerbations of systemic capillary leak syndrome complicating coronavirus disease. Emerging Infectious Diseases. 2021. (in press)

[24] Bahloul M, Ketata W, Lahyeni D, Mayoufi H, Kotti A, Smaoui F, et al. Pulmonary capillary leak syndrome following COVID-19 virus infection. Journal of Medical Virology. 2021; 93: 94–96.

[25] Case R, Ramaniuk A, Martin P, Simpson PJ, Harden C, Ataya A. Systemic Capillary Leak Syndrome Secondary to Coronavirus Disease 2019. Chest. 2020; 158: e267–e268.

[26] Lacout C, Rogez J, Orvain C, Nicot C, Rony L, Julien H, et al. A new diagnosis of systemic capillary leak syndrome in a patient with COVID-19. Rheumatology. 2021; 60: e19–e20.

[27] Wu MA, Fossali T, Pandolfi L, Carsana L, Ottolina D, Frangipane V, et al. Hypoalbuminemia in COVID-19: assessing the hypothesis for underlying pulmonary capillary leakage. Journal of Internal Medicine. 2021; 289: 861–872.

[28] Beber A, Dellai F, Abdel Jaber M, Peterlana D, Brunori G, Maino A. Systemic capillary leak syndrome triggered by SARS-CoV2 infection: case report and systematic review. Scandinavian Journal of Rheumatology. 2021. (in press)

[29] Roncati L, Corsi L. Nucleoside-modified messenger RNA COVID-19 vaccine platform. Journal of Medical Virology. 2021; 93: 4054–4057.

[30] Roncati L, Gallo G, Manenti A, Palmieri B. Renin-angiotensin system: the unexpected flaw inside the human immune system revealed by SARS-CoV-2. Medical Hypotheses. 2020; 140: 109686.

[31] Roncati L, Palmieri B. What about the original antigenic sin of the humans versus SARS-CoV-2? Medical Hypotheses. 2020; 142: 109824.

[32] Matheny M, Maleque N, Channell N, Eisch AR, Auld SC, Banerji A, et al. Severe exacerbations of systemic capillary leak syndrome after COVID-19 vaccination: a case series. Annals of Internal Medicine. 2021. (in press)

[33] Lambert M, Launay D, Hachulla E, Morell-Dubois S, Soland V, Queyrel V, et al. Highdose intravenous immunoglobulins dramatically reverse systemic capillary leak syndrome. Critical Care Medicine. 2008; 36: 2184–2187.

[34] Xie Z, Chan EC, Long LM, Nelson C, Druey KM. Highdose Intravenous Immunoglobulin Therapy for Systemic Capillary Leak Syndrome (Clarkson Disease). The American Journal of Medicine. 2015; 128: 91–95.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top